Provided by Tiger Fintech (Singapore) Pte. Ltd.

Agios Pharmaceuticals

40.00
-0.3500-0.87%
Post-market: 40.340.3386+0.85%19:06 EDT
Volume:824.55K
Turnover:33.30M
Market Cap:2.32B
PE:3.49
High:41.19
Open:40.70
Low:39.96
Close:40.35
Loading ...

Agios Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
01 May

Stock Track | Agios Pharmaceuticals Soars 7.51% Pre-Market on Strong Q1 Results and Pipeline Progress

Stock Track
·
01 May

Stock Track | Agios Pharmaceuticals Soars 7.51% Pre-Market on Strong Q1 Results and Pipeline Progress

Stock Track
·
01 May

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

Zacks
·
01 May

Agios Pharmaceuticals: Q1 Earnings Snapshot

Associated Press Finance
·
01 May

Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Loss of $-1.55, vs. FactSet Est of $-1.81 Loss

MT Newswires Live
·
01 May

Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Revenue $8.7M, vs. FactSet Est of $9.7M

MT Newswires Live
·
01 May

BRIEF-Agios Pharmaceuticals Q1 Product Revenue USD 8.726 Million

Reuters
·
01 May

Agios Pharmaceuticals Q1 Product Revenue USD 8.726 Million

THOMSON REUTERS
·
01 May

Agios: Phase 3 Rise Trial for Mitapivat in Sickle Cell on Track, With Topline Results Expected in Late 2025

THOMSON REUTERS
·
01 May

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire
·
01 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
01 May

U.S. RESEARCH ROUNDUP-Domino's Pizza, Prologis, Springworks Therapeutics

Reuters
·
29 Apr

Agios Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $50 From $51

THOMSON REUTERS
·
29 Apr

BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating

MT Newswires Live
·
17 Apr

Agios Pharmaceuticals price target lowered to $52 from $54 at BofA

TIPRANKS
·
17 Apr

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

GlobeNewswire
·
17 Apr

Agios Pharma (AGIO) Gets a Buy from Bank of America Securities

TIPRANKS
·
17 Apr

RBC Capital Sticks to Its Buy Rating for Agios Pharma (AGIO)

TIPRANKS
·
05 Apr

Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says

MT Newswires Live
·
03 Apr